---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-22-001470"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:53:43.379574+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcturus signs $200M upfront collaboration with CSL Seqirus for self-amplifying mRNA vaccines

## Summary
- Arcturus receives $200M upfront; eligible for >$1.3B development and >$3B commercial milestones.
- 40% net profit share on COVID-19 vaccines; up to double-digit royalties on flu, pandemic, and 3 other respiratory vaccines.
- Collaboration covers self-amplifying mRNA vaccines for COVID-19, influenza, pandemic preparedness, and three other respiratory diseases.
- CSL Seqirus leads development and commercialization; Arcturus provides STARR technology and LUNAR delivery platform.
- Transaction subject to HSR Act waiting period; J.P. Morgan advised Arcturus.

## SEC filing metadata
- accession: 0001193805-22-001470
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001470/0001193805-22-001470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001470/e617985_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-22-001470
- JSON: https://secwatch.observer/filing/0001193805-22-001470.json
- Plain text: https://secwatch.observer/filing/0001193805-22-001470.txt

## Key facts
- Material Agreements
  Arcturus Therapeutics Holdings Inc. entered into Collaboration and License Agreement with CSL Seqirus, Inc. valued at Up-front payment of $200 million; development milestones totaling more than $1.3 billion; commercial (effective 2022-11-01).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: CSL Seqirus, Inc.
  - Value: Up-front payment of $200 million; development milestones totaling more than $1.3 billion; commercial
  - Effective: 2022-11-01
  source text: On November 1, 2022, Arcturus Therapeutics Holdings Inc. ("Arcturus") entered into a Collaboration and License Agreement (the "Collaboration Agreement") with CSL Seqirus, Inc., a part of CSL Limited ("CSL Seqirus"), one of the world’s leading influenza vaccine providers, for the research, development, manufacture and global commercialization of self-amplifying mRNA vaccines.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001470/0001193805-22-001470-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.